This activity is supported by an unrestricted educational grant from Celgene Corporation and Takeda Oncology

Risk Stratification in Multiple Myeloma

Angela Mayo, MS, PA-C
Mayo Clinic Scottsdale

Craig B. Reeder, MD
Mayo Clinic Scottsdale

New innovative therapies in MM have increased significantly over the past decade and have improved survival rates.  Options now include proteasome inhibitors, immunomodulatory agents, HDAC inhibitors, monoclonal antibodies as well as standard chemotherapy. This activity equips the AP with critical updates in NCCN guidelines, diagnosis, risk-stratification, and treatment options, including: mechanism of action, side effect profile and supportive care.



 

Download Podcast

  
 
 

Download Transcript

 
 

Download Slides

 
 

Download Slides & Transcripts

  





These CE/CME/CEU accredited activities are jointly provided by

JADPRO Logo    Harborside Press Logo    APSHO Logo    Annenberg Logo
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me